Document ID: chunk:federal_register_of_legislation:F2025C00039:reg:73295
Version: federal_register_of_legislation:F2025C00039
Segment Type: reg
Provision Reference: reg 73295
Character Range: 6033–6986

73295              Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, requested by a specialist or consultant physician, to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme (PBS), in a patient with:                                                                                                                                                                                                                                                                                                                                                                                                 1,200.00
                     (a) advanced (FIGO III‑IV) high‑grade serous or high‑grade epithelial ovarian, fallopian tube or primary peritoneal cancer for whom testing of tumour tissue is not feasible; or
                     (b) breast cancer.

                   Applicable once per lifetime